Imidomics
1 known investors
IMIDomics discovers and develops first-in-class medicines for immune-mediated inflammatory diseases (IMIDs), using proprietary clinical and biomolecular patient data and bioinformatics to identify drug targets and patient-stratification markers. It targets eight diseases including lupus, ulcerative colitis, Crohn's disease and rheumatoid arthritis, drawing on a patient biobank built across recruiting centers in Spain.
AI & Machine LearningBiotechHealthtech
Founders & leadership
DC
Dr. CravesExecutive Chairman & CEO
Investors · 1
Frequently asked questions
- What does Imidomics do?
- IMIDomics discovers and develops first-in-class medicines for immune-mediated inflammatory diseases (IMIDs), using proprietary clinical and biomolecular patient data and bioinformatics to identify drug targets and patient-stratification markers. It targets eight diseases including lupus, ulcerative colitis, Crohn's disease and rheumatoid arthritis, drawing on a patient biobank built across recruiting centers in Spain.
- Who are Imidomics's investors?
- Imidomics's investors include Dns Capital.